JAK2 and myelodysplastic syndrome: The potential therapeutic targeting of ACVR1 raises promising prospects for MMB in treating other myeloid neoplasms characterized by ineffective erythropoiesis, such as myelodysplastic syndromes involving ring sideroblasts or the Splicing Factor 3B Subunit 1A (SF3B1) mutation, particularly when these conditions are co-expressed with a JAK2 mutation and thrombocytosis (34).